AAPG
Ascentage Pharma Group International
NASDAQ: AAPG · HEALTHCARE · BIOTECHNOLOGY
$21.66
+0.74% today
Updated 2026-05-11
Market cap
$2.01B
P/E ratio
—
P/S ratio
3.50x
EPS (TTM)
$-2.05
Dividend yield
—
52W range
$19 – $48
Volume
0.0M
WallStSmart proprietary scores
29
out of 100
Grade: F
Strong Sell
Investment rating
8.0
Growth
A4.3
Quality
C2.0
Profitability
F5.3
Valuation
C+2/9
Piotroski F-Score
Weak
-4.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →194 stocks currently score above 75
Price targets
Analyst target
$47.88
+121.05%
12-Month target
—
—
Intrinsic (DCF)
$26.39
Margin of safety
+6.78%
2 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 117.00% QoQ
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -4.15 — distress zone
- Thin margins at -216.50%
- Negative free cash flow $-787.41M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $209.71M | $221.98M | $980.65M | $558.48M | $574.12M |
| Net income | $-882.92M | $-925.64M | $-405.43M | $-1.21B | $-639.96M |
| EPS | — | — | — | — | $-2.05 |
| Free cash flow | $-890.88M | $-782.92M | $-135.65M | $-1.20B | $-787.41M |
| Profit margin | -421.02% | -416.98% | -41.34% | -216.47% | -216.50% |
Peer comparison
Smart narrative
Ascentage Pharma Group International trades at $21.66. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -4.15, it sits in the distress. TTM revenue stands at $574.12M. with profit margins at -216.50%. Our DCF model estimates intrinsic value at $26.39.
Frequently asked questions
What is Ascentage Pharma Group International's stock price?
Ascentage Pharma Group International (AAPG) trades at $21.66.
Is Ascentage Pharma Group International overvalued?
Smart Value Score 29/100 (Grade F, Strong Sell). DCF value $26.39.
What is the price target of Ascentage Pharma Group International (AAPG)?
The analyst target price is $47.88, representing +121.1% upside from the current price of $21.66.
What is the intrinsic value of Ascentage Pharma Group International (AAPG)?
Based on our DCF model, intrinsic value is $26.39, a +6.8% margin of safety versus $21.66.
What is Ascentage Pharma Group International's revenue?
TTM revenue is $574.12M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
-4.15 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio3.50x
ROE-154.60%
Beta0.72
50D MA$23.93
200D MA$31.07
Shares out0.09B
Float0.28B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—